Cargando…

Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus

Type I Interferon-mediated innate immunity against Flaviviridae, such as Hepatitis C virus (HCV) and Dengue virus (DENV), involves TLR3, RIG-I-like receptor (RLR) and JAK-STAT signal pathways. Asunaprevir is a newly developed HCV protease inhibitor for HCV treatment. Whether, asunaprevir activates i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Wei-Lun, Cheng, Jin-Shiung, Shu, Chih-Wen, Lai, Kwok-Hung, Chan, Hoi-Hung, Wu, Chun-Ching, Wu, Jing-Mei, Hsu, Ping-I, Chung, Raymond T., Chang, Tsung-Hsien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397474/ https://www.ncbi.nlm.nih.gov/pubmed/28473813 http://dx.doi.org/10.3389/fmicb.2017.00668

Ejemplares similares

Dengue Virus Replication Is Associated with Catecholamine Biosynthesis and Metabolism in Hepatocytes
por: Mpekoulis, George, et al.
Publicado: (2022)

Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase
por: Tsai, Wei-Lun, et al.
Publicado: (2017)

Hepatic Arterial Infusion Chemotherapy for Patients with Huge Unresectable Hepatocellular Carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2014)

Viperin is anti-viral in vitro but is dispensable for restricting dengue virus replication or induction of innate and inflammatory responses in vivo
por: Al Shujairi, Wisam-Hamzah, et al.
Publicado: (2021)

A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy
por: Chen, Wen-Chi, et al.
Publicado: (2015)

Lucidone suppresses dengue viral replication through the induction of heme oxygenase-1
por: Chen, Wei-Chun, et al.
Publicado: (2018)

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014)

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
por: Taki, Shinya, et al.
Publicado: (2018)

Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients
por: Tarao, Kazuo, et al.
Publicado: (2017)

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
por: Baba, Hayato, et al.
Publicado: (2016)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
por: Zhu, Li, et al.
Publicado: (2018)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

Clinical and Radiographic Outcomes of Inversed Restricted Kinematic Alignment Total Knee Arthroplasty by Asia Specific (Huang’s) Phenotypes, a Prospective Pilot Study
por: Hsieh, Shang-Lin, et al.
Publicado: (2023)

Comparison of Proton Pump Inhibitor and Histamine-2 Receptor Antagonist in the Prevention of Recurrent Peptic Ulcers/Erosions in Long-Term Low-Dose Aspirin Users: A Retrospective Cohort Study
por: Chen, Wen-Chi, et al.
Publicado: (2014)

Gallbladder function predicts subsequent biliary complications in patients with common bile duct stones after endoscopic treatment?
por: Tsai, Tzung-Jiun, et al.
Publicado: (2018)

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
por: Soumana, Djadé I., et al.
Publicado: (2014)

823 Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
por: de Ruiter, Petra E, et al.
Publicado: (2018)

Dengue Virus Targets the Adaptor Protein MITA to Subvert Host Innate Immunity
por: Yu, Chia-Yi, et al.
Publicado: (2012)

Ficus septica plant extracts for treating Dengue virus in vitro
por: Huang, Nan-Chieh, et al.
Publicado: (2017)

Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy
por: Uchida, Yoshihito, et al.
Publicado: (2018)

Modulating Innate Immunity Improves Hepatitis C Virus Infection and Replication in Stem Cell-Derived Hepatocytes
por: Zhou, Xiaoling, et al.
Publicado: (2014)

Impact of Intrahost NS5 Nucleotide Variations on Dengue Virus Replication
por: Cheng, Dayna, et al.
Publicado: (2022)

An HBV-encoded miRNA activates innate immunity to restrict HBV replication
por: Zhao, Xiaoqing, et al.
Publicado: (2019)

Study of Valproic Acid-Enhanced Hepatocyte Steatosis
por: Chang, Renin, et al.
Publicado: (2016)

USP18 enhances dengue virus replication by regulating mitochondrial DNA release
por: Lai, Jenn-Haung, et al.
Publicado: (2023)

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016)

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts
por: Lin, Kung-Hung, et al.
Publicado: (2012)

Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells
por: Tsai, Wei-Lun, et al.
Publicado: (2022)

The Efficacy of Endoscopic Papillary Balloon Dilation for Patients with Acute Biliary Pancreatitis
por: Sun, Wei-Chih, et al.
Publicado: (2015)

Is endoscopic treatment beneficial in patients with clinically suspicious of common bile duct stones but no obvious filling defects during the ERCP examination?
por: Chiang, Po-Hung, et al.
Publicado: (2016)

Functional innate immunity restricts Hepatitis C Virus infection in induced pluripotent stem cell–derived hepatocytes
por: Schöbel, Anja, et al.
Publicado: (2018)

Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions
por: Miyashima, Yuichi, et al.
Publicado: (2016)

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
por: Otsuka, Taiga, et al.
Publicado: (2017)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir
por: Sugiura, Ayumi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pqtvgcjink369urcp1ejsgllet